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ANTIMICROBIAL AGENTS IN LLAMAS
INTRODUCTION
Bacterial infections of the reproductive, gastrointestinal, and respiratory systems
are common problems in llamas (1,2,3). Due tothe behavioral characteristics of
llamas, bacterial infections and pathologic changes are frequently severe before
clinical changes are noted, making appropriate antibiotic selection and dosing of
paramount importance. Since the clearance characteristics of antibioticshave not
been established for many drugs in the llama, drug dosages and intervals have
been extrapolated from other species. While drug dosages extrapolated from
related species (e.g., dog to wolf) are frequently sufficiently accurate for
treatment of common bacterial infections, extrapolation across genera andfamily
lines is frequently inappropriate. This problem is particularly acute for the South
American Came lids (llama, alpaca, guanaco and vicuna). Since few drug's
dosages have been established for their closest phylogenetic relatives, the
bactrian and dromedary camels, drug dosages are frequently extrapolated from
those known for the cow, sheep and goat species distantly phylogenetically
related to the South American Came lids.
Species differences in dosage or administration rate (dose/dosing
interval) may be attributed to variations in pharmacokinetic behavior or2
pharmacodynamic activity or both. Comparative pharmacokinetic studies help to
explain differences in absorption and disposition processes between species in
response to fixed dosages of a drug (4). Species variations in pharmacokinetic
behavior of a drug in mammals are usually attributed to differences in the rate
of elimination rather than distribution and metabolism of the drug, although the
principle metabolic pathways may differ (4). The half-life values of drugs that
undergo extensive hepatic metabolism vary widely among the species of domestic
animals and humans. With certain notable exceptions, the herbivorous species
(horses and ruminant animals) metabolize lipid-soluble drugs more rapidly than
carnivorous species (dogs and cats). Humans metabolize drugs slowly in
comparison with animals, and generally have longer half-life values (4).
Inter species comparison of pharmacokinetic parameters between
other orders of animals (e.g., birds, fish, reptiles) show that variations may be
extreme. This can occur even when the principle elimination mechanism for the
drug is renal excretion (5). Most species differences in pharmacological effects
after a fixed dosage of a drug are due to variations in pharmacokinetic
characteristics of the drug, principally the rate of drug microsomal metabolism
(oxidative reactions and glucuronide synthesis) (4). These differences can
generally be accommodated by adjusting the dosage interval.3
Comparative pharmacokinetic studies provide a technique to clarify
differences in absorption and disposition processes between species in response
to a fixed dosage of a drug.
The number of llamas in North America are steadily increasing with
total population estimates varying between 40,000 and 60,000 animals. In light
of their high value and increasing popularity, it is appropriate to establish normal
drug distribution, disposition and elimination processes for representative
antimicrobial drugs in llamas. Antimicrobial drug dosages in the llama and
alpaca are frequently based on clearance characteristics determined in sheep due
to the similarity in weight and nutrient requirements. This approach overlooks
the fact that the Tylopoda (camel family) and the Bovidae (sheep and cattle)
diverged phylogenetically over 55 million years ago (6). It is also assumed that
since the Bovidae and Tylopoda have similar grazing habits and common species
of commensal bacteria and protozoa, that intestinal drug absorption is handled
in the same manner. This assumption is probably unwarranted in at least some
situations since the Bovidae is a four compartment animal gastro-intestinally
while the Came lids have a total of three compartments with only the distal 20%
of the third compartment being the functional equivalent of the abomasum.
There is also good evidence that the absorptive capabilities of the large first
compartment (C-1) are significantly different than the rumen of the cow and
sheep (3).4
When drug dosages are extrapolated across speciesline, the
assumption being made is that the pharmacokinetic parameters remain constant.
As illustrated in Table 1-4, these assumptions are frequently invalid resulting in
under or over dosing of a pharmaceutical. To date there have been no critical
pharmacokinetic evaluations of antimicrobial drugs for use in llamas to verify if
extrapolation of drug dosages from other species is appropriate.
Table 1. Species comparison of pharmacokinetic values of Enrofloxacin for
poultry, calves, rabbits and fish after a single IV bolus dose (7-10).
Para-
meter
Units TurkeyChickenCalf RabbitFish
t12 h 4.1 18.7 2.7 2.5 24.4
CL ml/h/kg532 134 204 606 91.6
Vd,, 1/kg 3.16 3.61 0.77 2.12 3.22
AUC tig.h/m118.82 37.3 26.7 8.6 109.2
Table 2. Species comparison of pharmacokinetic values of Ampicillin for sheep,
mice, horse and humans after a single IV bolus dose (11-14).
Para Units Sheep Mice Horse Human
meter
t12 h 0.79 0.96 1.6 1.09
CL ml/h/kg327.6 360.0 216.2
Vdarea 1/kg 0.52 0.38 0.34
AUC tig.h/m134.51 111.37 55.85
Table 3. Species comparison of pharmacokinetic values of Tobramycin for cats
and humans after a single IV bolus dose (15-16).
Para Units Cat Human
meter
t12 h 1.84 1.59
CL ml/h/kg132.6 105.0
Vd. 1/kg 0.20 0.241
AUC gg.h/m18.16
Table 4. Species comparison of pharmacokinetic values of Trimethoprim for rats
and horse after a single IV bolus dose (17,18,49).
Para Units Rat HorseHuman
meter
t1/2 h 1.65 3.92 14.6
CL ml/h/kg3120 72
Vdarm 1/kg 5.73 0.39
AUC Ag.h/m11.25 201.07
Establishmentofappropriatetherapeuticregimensrequires
determination of a drug's half-life, clearance and volume of distribution (19).
Once these parameters have been established, drug dosing can be established in
order to maintain a minimum inhibitory concentration (MIC) of the
pharmaceutical. The lack of information about drug disposition in llamas led to6
this study, which was to evaluate the pharmacokinetics of four commonly used
antimicrobials from four separate classes of drugs. The results of this study will
begin to provide a rational basis for therapeutic treatment of infectious diseases
in llamas. By testing the antimicrobials in llamas, and determining their
pharmacokinetic parameters, the probability of developing appropriate drug
dosing schedules should significantly increase and greatly aid in therapy.
Developing drug dosing schedules from thisstudy may aid veterinary
practitioners in their attempt to extrapolate other antimicrobial drug dosages
from other species to llamas.
The fourclassesof drugs areasfollows, with the chosen
representative to be used in this study appearing directly behind.
PENICILLIN --- AMPICILLIN(Amp-EquineR)
SULFA --- TRIMETHOPRIM(TribrissenR)
FLUOROQUINOLONE--- ENROFLOXACIN(BaytrilR)
AMINOGLYCOSIDE --- TOBRAMYCIN(NebcinR)7
Specific Objectives:
The over all objectives of this study were to test the following hypothesis:
The drug disposition characteristics (clearance, half-life, apparent
volume of distribution and mean residence time) used to calculate drug dosages
and dosing intervals are similar to extrapolated dosages and dosing intervals
from other ruminant species for the four commonly used antimicrobials from the
four separate classes of drugs.8
LITERATURE REVIEW
Both Gram negative and Gram positive bacterial infections are
common problems in the llamas (20,21). While vaccination programs have
effectively decreased the incidence of clostridial infection, mixed bacterial
respiratory,gastrointestinalandreproductiveinfectionsarefrequently
encountered (20). Respiratory and Uterine infections are of particular concern
since the damage is frequently extensive prior to the time that overt clinical
changes are noted.
Therapy of an infectious disease in the llama is dependent upon the
microorganism involved. Numerous penicillins and cephalosporins are available
in human medicine. In general they are considered bactericidal agents since they
inhibit bacterial cell wall synthesis (22-24). Ampicillin has excellent activity
against gram positive organisms and gram negative cocci, but limited activity
against gram negative bacilli (22,24). Extended spectrum penicillins, ticarcillin
and piperacillin (Ticar, Piperacil etc.), which were the first penicillins to achieve
significant activity against gram negative bacteria (24), have structures initially
based upon ampicillin.
Penicillins and Cephalosporins are typically handled similarly in the
body. They are excreted extensively unmetabolized into the urine via the kidney
and have half-lives that are typically under 1.5 hours in humans. Ampicillin's
half-lives after intravenous injection in relation to body mass in some species of9
mammals and birds are reported as 1.72, 2.0, 1.58, 0.7, 0.53, 0.69, 0.31 and 0.56
hours in buffalo, cow, sheep, goat, pig, rabbit, pigeon and chickens respectively
(19).
Trimethoprim, a broad spectrum antibiotic with excellent activity
against gram positive organisms is excreted much more slowly (t1,20 = 5.5 hours)
and metabolized to a greater extent (25). Trimethoprim acts as a folate
antagonist by inhibiting dihydrofolate reductase and is often used in combination
with the sulfonamide class of drugs (51). Species differences in the rate and
extent of the various routes of the elimination processes for trimethoprim reflect
the diverse half-life values of the drug; 0.7 to 1.5, 3.2, 4.6 and 10.6 hours in
ruminants, horses, dogs and humans respectively (4).
Aminoglycosides like tobramycin have extensive activity against gram
negative organisms (24). New antibiotics like the extended activity penicillins and
cephalosporins are routinely compared against the aminoglycoside class of drugs
for their effectiveness against gram negative organisms (24). In general,
tobramycin must be given parenterally. It is excreted essentially unmetabolized
into the urine via the kidney and its half-life and clearance is influenced by the
renal function of the individual (26-28).
The fluroquinolone class of antibacterials, derivatives of nalidixic acid,
have recently received considerable attention in the veterinary field because of
their broad spectrum of activity, good absorption after oral administration, low10
toxicity, and long elimination half-life (29). They are more active against gram
negative organisms, but have so far shown no activity against Pseudomonas
aeruginosa (29). Fluroquinolone antibacterials possess a broad spectrum of
activity against gram-negative bacteria, such as E.coli, Salmonella, Klebsiella,
Proteus, Haemophylus, Pasteurella and Campylobactur (52).
Microbial resistance to fluroquinolone derivatives is slower than to
Nalidixicacid,and fluroquinolonesextremely low minimum inhibitory
concentrations have accelerated their use (29,32-34). Enrofloxacin is similar in
structure, activity and use to the human drug ciprofloxacin (29,33). The
microbiological activity of the fluroquinolones is thought to be due to the
inhibition of bacterial DNA gyrase enzyme (32). This includes cleavage of the
DNA backbone, presumably a bactericidal effect. Other mechanisms of activity
also may exist. Enrofloxacin has poor oral absorption in ruminant animals and
is given parenterally (29). Enrofloxacin's half-life varies considerably between
species. Half lives (t m) of 7.3, 1.4, 1.2, 2.1 and 3.3 hours have been reported for
the chicken, turkey, calf, dog and horse respectively (29). Bacterial diseases
which have been reported to affect llamas appear to be susceptible to one of the
four antimicrobial agents selected in this study.11
MATERIALS AND METHODS
Animals: Six sexually mature males in the OSU Came lid research herd were
used. All animals were medically sound. Prior to initiation of experiments all
animals were held in quarantine for at least one week, vaccinated and dewormed
as needed, given a complete physical examination and any routine health care
as indicated.
Drug Solutions: Parenteral solutions of ampicillin, trimethoprim, tobramycin,
enrofloxacin and ceftiofur were obtained from commercial sources.
Drug solutions were administered by the intravenous bolus route in
the sequence of administration shown below. Doses (all doses were equivalent
to human dose) given were as follows:
a.Ampicillin Sodium (Amp-equine') 12 mg/kg
b.Tobramycin (Nebcin') 1.0 mg/kg
c.Trimethoprim Sulfa (Tribrissen') 3.0 mg/kg
d.Enrofloxacin (Baytril') 5.0 mg/kg
e.Ceftiofur Sodium (Naxcel') 2.2 mg/kg12
Blood samples were collected for 12 hours for each treatment
followed by three days of no drug administration before the next drug treatment
was administered.
From the five drugs only ampicillin, tobramycin, trimethoprim and
enrofloxacin are included in this report.
Sampling protocol:
Approximately 24 hours prior to starting the study an indwelling
catheter was placed in the jugular vein and fitted with a catheter extension. A
local lidocaine block was used to minimize the discomfort associated with
catheter placement. Food and water was made available ad libitum. Drug
solutions were administered as bolus intravenous dose to the animals through the
indwelling catheter, then the catheter was immediately flushed with saline. Blood
samples (7 ml Vacutainer) were collected via the catheter immediately before
drug administration and 5 min, 10 min, 15 min, 30 min, 45 min, 1 hr, 1.5 hr,
2 hr, 3 hr, 4 hr, 6 hr, 8 hr and 12 hr after drug administration. After a blood
sample was collected the catheter was flushed with normal saline solution. After
collection of the blood sample, the sample was centrifuged, the plasma decanted
and frozen for storage until assay.13
Materials used for assays were all analytical grade without further
purification. All water was deionized prior to use.
AMPICILLIN ASSAY PROCEDURE
Materials: Ampicillin and 13- hydroxyethyl theophylline were obtained from Sigma
Chemical Co., Methanol (HPLC grade) was obtained from both Sigma and
Aldrich Chemical Co., and Potassium phosphate monobasic was obtained from
Aldrich Chemical Co., Inc.
Internal Standard Solution
13-Hydroxyethyl theophylline (25 mg) was dissolved in 100 ml distilled water.
Forty ml of this solution was transferred to a 100 ml volumetric flask and
distilled water was added to bring up to 100 ml volume. Final concentration was
100 µg /ml.
Sample Preparation
To 0.5 ml of plasma sample, 1.0 ml of methanol was added to deproteinize the
plasma. After vortex mixing and centrifuging at 240th g for 10 min in an
Eppendorf centrifuge (model 5415 C), 1.0 ml of supernatant was separated and14
25 Al of (100 µg /m1) internal standard (3-hydroxyethyl theophylline) was added
and mixed. Then 150 Al of supernatant was injected into the HPLC.
Chromatograph Specifications
The HPLC system (HEWLETT PACKARD, Model LC 1090 M)
consisting of a HPLC Pump (Model 100/120 V Ac, 60 Hz, Hewlett Packard) and
an Auto sampler (Model 1090 M, #48, Hewlett Packard) was used. The drug
was separated on C-18 Column (ABondapak, Water Associate, Inc.) using an UV
Detector (Diode Array Detector with Deuterium lamp with a spectrum from 190
nm to 600 nm, UV Absorbance, Hewlett Packard). DAD (Diode Array Detector)
signals were set at Sample Wavelength of 205 nm with a Band Width of 4 nm
and a Reference Wavelength of 550 nm. The initial threshold was set at 0.1
mAU (absorbance units) with a peak width of 0.1 min (Sampling interval = 640
ms). The flow rate of the mobile phase was 1.0 ml/min and Injection Volume
was 150 Al (37) .
Mobile Phase consisted of methanol and phosphate buffer (0.067 M)
in the ratio of 35:65 respectively. Mobile phase was filtered through 0.47 Am
filter and degassed by sonicating under vacuum for about 15 minutes. The
chromatographic condition was isocratic (37).15
Standard Curve: Stock solution of ampicillin (25 mg in 100 ml of distilled water)
was prepared. Serial dilutions with blank (drug free) llama plasma of this stock
solution were made in duplicate to obtain the following concentrations of 1, 5,
10, 25, 50 and 100 µg /ml. Three standard curves (six points each) were run over
a period of three weeks. Ampicillin and the internal standard (fl-hydroxy ethyl
theophylline) peaks were clearly separated and eluted within 15 minutes. Mean
retention times for ampicillin and fl-hydroxyethyl theophylline were 9.3 and 6.4
minutes respectively.
Care was taken to prepare the stock ampicillin solution ( 25 mg in
100 ml distilled water) fresh every time the standard curve was run. After
samples were prepared they were immediately injected into the HPLC system.
The pH of the ampicillin stock solution was between 7.0 to 7.5 to ensure its
stability.
Standard curve for ampicillin is shown in Fig 1. Peak height ratios and
regression results are shown in Table 5.16
TABLE 5. VALUES USED IN THE GENERATION OF THE STANDARD
CURVE TO DETERMINE UNKNOWN AMPICILLIN PLASMA
CONCENTRATIONS IN LLAMA.
CONCN1 DRUG'IS' RESP4%THEO5
1 43.25 435.26 44.02 101.7
5 212.24 425.28 208.90 98.4
10 405.36 436.98 415.00 102.4
25 894.76 426.94 1033.3 115.5
50 1802.27425.28 2063.8 114.5
100 3560.44428.50 4124.8 115.8
X6 =108.05; S.D.' =8.03; % CV' = 7.68
1
'Results of regression of response on actual concentration:
R2= 0.999; Intercept = 2.80; Slope = 41.22
I. Actual concentration of ampicillin (pug /ml)
2.Drug = Area under the peak on chromatogram for ampicillin.
3. IS = Area under the peak on chromatogram for internal standard.
4.Response = (Slope * Amount) + Intercept, which equals predicted ampicillin
concentration.
5.%THEO = Percent theoretical concentration of ampicillin.
6. Mean percent theoretical concentration.
7. Standard deviation of the mean.
8. Coefficient of variation as a percent of the mean.17
FIG 1. STANDARD CURVE FOR AMPICILLIN FROM HPLC ANALYSIS
USED TO DETERMINE UNKNOWN PLASMA AMPICILLIN
CONCENTRATIONS.
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TOBRAMYCIN ASSAY PROCEDURE
Materials: Tobramycin, gentamycin, tris(hydroxymethyl) aminomethane and
2,4,6-trinitrobenzene-1-sulfonic acid (TNBSA) were obtained from Sigma
Chemical Co. Acetonitrile (HPLC grade) and methanol (HPLC grade) were
supplied by both the Sigma and Aldrich Chemical Co. Potassium phosphate,
monobasic was obtained from Aldrich Chemical Co. C-18 columns, the solid-
phase extraction came from J.T. Baker Chemical Co., and the Vac-Elut vacuum
chamber was obtained from Analytichem International, Inc.
Reagents and solutions were prepared as follows:
Tris Buffer, 2 mol/L, pH 10.3 was prepared by dissolving 24.2 gm of Tris
(hydroxymethyl) aminomethane in distilled water and the volume was adjusted
to 100 ml. 2,4,6-Trinitrobenzene-1-sulfonic acid derivatizing solution, 250 g/L was
prepared by dissolving 2.5 g of trinitrobenzene sulfonic acid (TNBSA, Sigma) in
10 ml of acetonitrile. Stock Wash Buffer, 1 mol/L was prepared by dissolving 87
gm of potassium phosphate, monobasic in 500 ml of distilled water. Working
Wash Solution, a methanol/phosphate buffer solution (0.1 mol/L, pH 8.5, 50/50
V/V) was prepared by transferring 10 ml of stock wash buffer into a 250 ml
graduated cylinder and 90 ml of distilled water was added followed with 100 ml
of methanol. pH of this solution was adjusted to 8.5 with phosphoric acid. The19
mobile phase for the HPLC consisted of 700 ml of acetonitrile and 300 ml of 50
mMol/L phosphate buffer (6.8 gm of potassium phosphate, monobasic per liter
of water). pH was adjusted to 3.5 with phosphoric acid. Mobile phase was
filtered through 0.47 pm filter and degassed by sonicating under vacuum for 15
minutes.
Internal Standard Solution
Gentamycin (25 mg) was dissolved in 100 ml distilled water. Forty ml of this
solution was transferred to 100 ml of volumetric flask and distilled water was
added to bring the volume up to 100 ml. Final concentration was 100 Ag/ml.
Internal standard (Gentamycin) was separately derivatized according to the
procedure described below and then added to the derivatized tobramycin sample.
Sample Preparation
Derivatization and Solid-Phase Extraction Procedure
Fifty Al of tobramycin plasma samples were pipetted into 1.5 ml polypropylene
tubes and 25 gl of 2 mol/L Tris buffer and 100 Al of acetonitrile were added,
vortex mixed and centrifuged for 1 min in an Eppendorf centrifuge (Model 5415
C) at 15,000x g. Supernatant was decanted into a second set of appropriately
labeled polypropylene tubes and 30 Al of TNBSA (2,4,6-Trinitrobenzene -20
1-Sulfonic acid) was added. Tubes were capped, vortex mixed and placed on a
hot plate, heated at 70°c for 30 min. For each sample, a Bond-Elut C-18
extraction column was placed on the top of Vac-Elut vacuum chamber and
vacuum was connected to the chamber. Two column volumes of methanol and
two column volumes of water was passed through each column. The vacuum was
disconnected and each column was filled with 700 /21 of working wash solution,
followed by approximately 200 /.41 of derivatized sample. Vacuum was then
reconnected to the chamber and three column volumes of working wash solution
was passed through each column. Vacuum was disconnected and a rack of
labelled glass tubes were placed on the Vac-Elut chamber, corresponding to each
Bond-Elut column. Then 300 /21 of acetonitrile was pipetted onto each column
and vacuum was reconnected. After collecting the eluate in the tubes, 25 Al of
similarly derivatized and extracted internal standard (Gentamycin) was added to
each tube and mixed. Tobramycin and gentamycin could not be derivatized
together as they competed for the derivatizing agent resulting in the incomplete
derivatization of the tobramycin. 150 yl of the extracted sample was injected
onto the HPLC system (36).
Optimal Conditions for derivatization:
Optimal conditions for derivatization were arrived at by varying
reagent concentration, reaction temperature, reaction time and pH. A large21
excess of the derivatizing agent (TNBSA) was necessary to yield a single
tobramycin derivative quantitatively in < 30 min. (TNBSA reacts with primary
amino groups of amino acids and peptides in aqueous solutions at pH 8 without
any undesirable side reactions). The resulting trinitrophenyl derivatives had a
high molar absorptivity at 340 nm. At temperatures below 70°C there was
incomplete derivatization and above 80°C there was substantial decomposition.
The optimal conditions for derivatization of tobramycin of 70°c and 30 min
reaction time were selected. Below pH 9.0, derivatization was incomplete and
slow because of the basic nature of the tobramycin molecule. The optimal pH
for this reaction was between 9.5 and 10.0 (36).
Chromatograph Specifications
The HPLC System (Model LC 1090M, HEWLETT PACKARD)
consisting of a HPLC Pump (Model 100/120 V Ac, 60 Hz, Hewlett Packard) and
an Auto sampler (Model HP 1090 M, # 048, Hewlett Packard) was used. The
drug was separated on a C-18 Column (Microsorb -MV, Rainin Instrument Co.,
Inc.) using a UV detector (Diode Array Detector with a Deuterium lamp with
a spectrum of 190 nm to 600 nm, UV Absorbance, Hewlett Packard).
DAD(Diode Array Detector) signals were set at Sample Wavelength of 340 nm
with a Band width of 4 nm and a Reference Wavelength of 550 nm. The initial
threshold was set at 0.1 mAU (absorbance units) with a peak width of 0.1 min22
(Sampling interval = 640 ms). The flow rate of the mobile phase was 1.0 ml/min
and Injection Volume was 150 id. The chromatographic condition was isocratic
(36).
Standard Curve: Stock solution of tobramycin 25 mg in 100 ml of distilled water
was prepared. Serial dilutions with blank (drug free) llama plasma of this stock
solution were made in duplicate to obtain the following concentrations of 1, 5,
10, 25, 50 and 100 µg /ml. Standard samples were derivatized and extracted as
described for the unknown samples.
Four standard curves (six points each) were run over a period of four
weeks. Tobramycin and internal standard (gentamycin) peaks were clearly
separated and eluted within 22 minutes. Mean retention time for tobramycin was
19.7 minutes. Internal standard (gentamycin) had three components C1, Cia and
C2 with retention times for each of the components of 13.8, 16.0 and 17.3
minutes respectively. The component peak with retention time of 13.8 minutes
was used as internal standard peak to calibrate tobramycin samples.
Standard curve for Tobramycin is shown in Fig 2. Peak height ratios
and regression results are shown in Table 6.23
TABLE 6. VALUES USED IN THE GENERATION OF THE STANDARD
CURVE TO DETERMINE UNKNOWN TOBRAMYCIN PLASMA
CONCENTRATIONS IN LLAMA.
CONCN1 DRUG'IS' RESP4%THEO'
1 43.234 214.43 41.02 94.8
5 180.01 217.20 177.82 98.8
10 383.06 229.27 348.82 91.1
25 846.50 231.27 861.82 101.7
50 1724.4 219.25 1718.6299.7
100 3425.2 214.34 3426.82100.0
X6 = 97.65; S.D.' = 3.86; % CV' = 3.95
2
2Results of regression of response on actual concentration:
R2= 1.000; Intercept = 6.82; Slope = 34.2
1.Actual concentration of tobramycin (pug /ml)
2.Drug = Area under the peak concentration for tobramycin.
3. IS = Area under the peak on chromatogram for gentamycin the internal
standard.
4.Response = (Slope * Amount) + Intercept, which equals the predicted
tobramycin concentration.
5.%THEO = Percent theoretical concentration of tobramycin.
6.Mean percent theoretical concentration.
7.Standard deviation of the mean.
8.Coefficient of variation as a percent of the mean.24
FIG 2. STANDARD CURVE FOR TOBRAMYCIN FROM HPLC ANALYSIS
USED TO DETERMINE UNKNOWN PLASMA TOBRAMYCIN
CONCENTRATIONS.
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TRIMETHOPRIM ASSAY PROCEDURE
Materials: Trimethoprim and antipyrine were obtained from Sigma Chemical Co.
Potassium phosphate, dibasic and perchloric acid were supplied by Aldrich
Chemical Co., Inc. Methanol (HPLC grade) was obtained from both the Sigma
and Aldrich Chemical Co.
Internal Standard Solution
Antipyrine (100 mg) was dissolved in 100 ml distilled water. 10 ml of this
solution was transferred to a 100 ml volumetric flask and distilled water was
added to bring the volume up to 100 ml. Final concentration was 100 µg /ml.
Sample Preparation
To 100 Al of the trimethoprim plasma sample, 100 µl of 1 mol/L perchloric acid
and 25 Al of 100 µg /ml of internal standard (antipyrine) were added together.
The mixture was vortexed and centrifuged for 5 minutes in an Eppendorf
centrifuge (model 5415 C) at 500th g. To 150 ml of the supernatant, 150 Al of
(0.5 mol/L) dibasic potassium phosphate was added and after through mixing the
sample was centrifuged again for 5 minutes at 5000x g. The 30 id of the final
supernatant was injected onto the HPLC.26
Chromatograph Specification
The HPLC system consisting of a HPLC Pump (Model M-600 A;
Water Associate, Inc) and a WISP auto sampler (Model 710 B Water Associate,
Inc) was used. The drug was separated on a ABondapak C-18 Column (Water
Associate, Inc) using a UV detector (Series 440, UV Absorbance; Water
Associate, Inc) with mercury lamp and filter at 280 nm and sensitivity set at 0.05
absorbance units. A recorder (Linear Inc.) set at a chart speed 6 cm/hr received
signal from the detector at a 10 mV scale. The mobile phase consisted of
methanol and phosphate buffer (0.05 mol/L, pH 4.4) in the ratio of 30:70
respectively. Mobile phase was filtered through 0.47 Am filter and degassed by
sonicating under vacuum for about 15 minutes. The flow rate of the mobile
phase was 1 ml/min and the injection volume was 30 Al. The chromatographic
condition was isocratic (25).
Standard Curve: A stock solution of trimethoprim (15 mg in 100 ml of distilled
water) was prepared. Serial dilutions with blank (drug free) llama plasma with
this stock solution were made in duplicate to obtain the following trimethoprim
concentrations of 1, 2, 5, 10, 15 and 20 µg /ml.
Four standard curves (six points each) were run over a period of three
weeks. Trimethoprim and the internal standard (antipyrine) peaks were clearly
separated and eluted within 10 minutes.27
Mean retention times for trimethoprim and antipyrine were 6.0 and
7.9 minutes respectively.
Standard curve for trimethoprim is shown in Fig 3. Peak height ratios
and regression results are shown in Table 7.28
TABLE 7. VALUES USED IN THE GENERATION OF THE STANDARD
CURVE TO DETERMINE UNKNOWN TRIMETHOPRIM PLASMA
CONCENTRATIONS IN LLAMA.
CONCN1 DRUG2IS' PHR4INV %THEO6
1 1.05 8.9 0.118 0.877 87.7
2 2.35 8.93 0.264 2.087 104.3
5 5.45 8.8 0.620 5.037 100.7
10 11.03 9.1 1.212 9.943 99.4
15 15.33 8.3 1.845 15.188 101.2
20 21.58 8.95 2.412 19.887 99.4
7,5
X' =98.78
S.D.' = 5.22
% CV 9 = 5.28
3
3Results of regression of Peak Height Ratio on actual concentration:
R = 0.9998; Intercept = 0.01222; Slope = 0.1206
1.Actual concentration of trimethoprim (Ng /ml)
2.Drug = Height of drug peak on chromatogram (mm) for trimethoprim.
3.IS = Height of internal standard peak on chromatogram (mm) for antipyrine.
4.PHR = Peak Height Ratio (Drug/IS: Trimethoprim/Antipyrine).
5.Inverse = Inversely estimated trimethoprim concentrations calculated from PHR
and regression parameters by the equation:
Inverse = (PHR Intercept)/Slope
6.% THEO = Percent Theoretical Concentration of trimethoprim.
7.Mean percent theoretical concentration.
8.Standard deviation of the mean.
9.Coefficient of variation as a percent of the mean.29
FIG 3. STANDARD CURVE FOR TRIMETHOPRIM FROM HPLC
ANALYSIS USED TO DETERMINE UNKNOWN PLASMA
TRIMETHOPRIM CONCENTRATIONS.
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ENROFLOXACIN ASSAY PROCEDURE
Materials: Enrofloxacin was obtained from Mobay Corporation. Cefazolin was
obtained from Sigma Chemical Co. Methanol (HPLC grade) and acetonitrile
(HPLC grade) were supplied by both the Sigma and Aldrich Chemical Co., Inc.
Potassium phosphate, monobasic was obtained from Aldrich Chemical Co.
Internal Standard Solution
Cefazolin (100 mg) was dissolved in 100 ml distilled water. Ten ml of this
solution was transferred to 100 ml volumetric flask and distilled water was added
to bring up to 100 ml volume. Final concentration was 100 µg /ml.
Sample Preparation
To 50 Al of enrofloxacin plasma sample, 50 .d of acetonitrile was added and the
mixture was vortex mixed and centrifuged (10,000x g) in an Eppendorf centrifuge
(model 5415 C). Twenty five Al of (100 µg /ml) internal standard (cefazolin) was
added to the deproteinized plasma sample and mixed. Twenty gl of the clear
supernatant was injected onto the HPLC.31
Chromatograph Specification
The HPLC system consisting of a HPLC Pump (model M-600 A;
Water Associates, Inc) and a WISP auto sampler (model 710 B; Water
Associates, Inc) was used. The drug was separated on a tiBondapak C-18 Column
(Water Associates, Inc) using a UV detector (Series 440, UV Absorbance; Water
Associates, Inc) with a mercury lamp and filter at 280 nm and a sensitivity set
at 0.05 absorbance units. A recorder (Linear Inc.) set at chart speed of 6 cm/hr
received signal from the detector at a 10 mV scale. The mobile phase consisted
of methanol and phosphate buffer (67 mMol/L, pH 3.5) in the ratio of 35:65
respectively. Mobile phase was filtered through 0.47 pm filter and degassed by
sonicating under vacuum for about 15 minutes. The flow rate of the mobile
phase was 1.0 nil/min and the injection volume was 20 pl. The chromatographic
condition was isocratic (35).
Standard Curve: A stock solution of enrofloxacin (25 mg in 100 ml distilled
water) was prepared. Serial dilutions with blank (drug free) llama plasma of this
stock solution were made in duplicate to obtain the following enrofloxacin
concentrations of 1, 2, 4, 8, 16, 24 and 32 µg /ml.
Six standard curves (seven points each) were run over a period of four
weeks. Enrofloxacin and the internal standard (cefazolin) were clearly separated
and eluted within 10 minutes with the mean retention times of 8.4 and 5.232
minutes respectively. Internal standard (cefazolin) was freshly prepared each
time the standard curve was run.
Standard curve for enrofloxacin is shown in Fig 4. Peak height ratios
and regression results are shown in Table 8.33
TABLE 8 VALUES USED IN THE GENERATION OF THE STANDARD
CURVE TO DETERMINE UNKNOWN ENROFLOXACIN PLASMA
CONCENTRATIONS IN LLAMA.
CONCN1 DRUG'IS3 PHR4 INV' %THEO6
1.00 0.3 6.7 0.045 1.39 139.7
2.00 0.6 7.6 0.080 2.13 106.4
4.01 1.1 7.1 0.155 3.69 92.1
8.02 3.15 9.05 0.348 7.72 96.3
16.04 6.75 9.15 0.738 15.87 98.93
24.12 10.3 8.95 1.151 24.49 101.5
32.08 14.5 9.6 1.509 31.97 99.7
X7 = 104.9; S.D.' = 14.76; % CV9 = 13.87
4
4Results of regression on actual concentration: R = 0.999;
Intercept = 0.02195; Slope = 0.04789
1.Actual concentration of enrofloxacin (Ng /m1).
2.Drug = Height of drug peak on chromatogram (mm) for enrofloxacin.
3. IS = Height of internal standard peak on chromatogram (mm) for cefazolin.
4. PHR = Peak Height Ratio (Drug/IS: Enrofloxacin/Cefazolin).
5. Inverse = Inversely estimated enrofloxacin concentration calculated from PHR
and regression parameters by the equation:
Inverse = (PHR Intercept)/Slope.
6.% THEO = Percent of theoretical concentration for enrofloxacin.
7.Mean percent of the mean.
8.Standard deviation of the mean.
9.Coefficient of variation as a percent of the mean.34
FIG 4. STANDARD CURVE FOR ENROFLOXACIN FROM HPLC
ANALYSIS USED TO DETERMINE UNKNOWN PLASMA
ENROFLOXACIN CONCENTRATIONS.
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Pharmacokinetic Analysis:
Ampicillin, Tobramycin, Trimethoprim and Enrofloxacin plasma
concentrations versus time data were analyzed using RSTRIP Computer Software
(30) to fit the data. Using both the compartmental and non-compartmental
approaches the pharmacokinetic parameters of half-lives, clearances, apparent
volumes of distribution and mean residence times were calculated (31,38,39,40).
The following specific objectives were addressed or elucidated:
1.To determine and compare the disposition and elimination characteristics
of the representative member of the four most commonly used classes of
antimicrobials after bolus IV administration.
2.Characterizethe pharmacokinetic parametersof theantimicrobials
(clearance, half-life, apparent volume of distribution and mean residence time)
to identify if significant differences in these pharmacokinetic parameters occur
than would be expected by extrapolation or scaling from other species.
3.Estimate the therapeutic duration of action and dosing intervals necessary
for the adequate therapy for each representative agent of the therapeutic classes.
The plasma concentration time data of each antimicrobial was fit
using RSTRIP Computer Software. The data was weighted 1/(concn)2 to get a36
best fit. Drug concentrations in llama plasma after bolus IV administration were
individually fitted to a 1, 2 or 3 compartment open model for kinetic analysis,
with the first order elimination from the central compartment. Non-linear least
squares fit of each set of data was obtained using the number of terms required
for each llama.
Goodness of fit was based on improvement in sum of squares, model
selection criterion and values of coefficient of determination.RESULTS
AMPICILLIN
37
Mean plasma concentrations of ampicillin at each sampling time are
shown in table 9. The post-distribution clearance values for ampicillin are
presented in table 10. The clearance values indicate ampicillin follows linear
pharmacokinetics in llama.
Plasma concentrations of ampicillin as a function of time after bolus
IV administration in each llama were fitted to a two exponential equation. Non-
linear least squares fit of each set of data to the general equation:
Cp = E Ai Eq. 1.
was obtained but using the number of terms required for each subject. Where
Cp is the ampicillin plasma concentration, X, are the exponents, Ati are the pre-
exponential coefficients and t is time.
Plasma ampicillin concentrations after IV bolus administration for all
six llama's required two exponential function:
Cp = Ale" + A2e't Eq. 2.38
to characterize the declining plasma ampicillin concentrations as a function of
time. Cp is the ampicillin plasma concentration, X, and X, are distribution and
elimination rate constants and t is time.
The determination of the best fit compartment model and estimates
of the model dependent pharmacokinetic parameters (41-44) of A1, A2, X1, X2, lc
and V, were made by the use of RSTRIP (30). Statistical moments theory was
used to compute the non-compartmental model pharmacokinetic parameters of
mean residence time (MRT), apparent volume of distribution (V d), apparent
volume of distribution at steady-state (Vds,), body clearance (CLB) and area
under the curve (AUC) (42-45).
Plasma ampicillin concentration vs. time curves from all six llama's
were analyzed individually. Mean values for each pharmacokinetic parameter for
a compartmental and a non-compartmental model were computed with their
standard deviation and are shown in tables 11 and 12 respectively.
Mean curve of plasma concentrations vs. time after IV bolus
administration of ampicillin is shown in fig 5.
Pharmacokinetics of ampicillin after bolus IV administration in all
llama's fitted (correlation coefficient > 0.99) a two compartmental model with
a = 1.12 ± 0.58 and fi = 0.208 ± 0.050. The plasma half-life (t112,3) of ampicillin
was 3.50 ± 1.01 hours.39
The mean residence time (MRT) of ampicillin was 5.01 ± 0.66 hours
and volume of distribution at steady state (Vdss) was 0.277 ± 0.085 1/kg.40
TABLE 9. DRUG CONCENTRATION Vs. TIME DATA OF SIX LLAMA'S RECEIVING AN IV DOSE OF
12 mg/kg OF AMPICILLIN.
TIME CONCN
(µg /ml)
LLAMA
CONCN
LLAMA
CONCN
LLAMA
CONCN
LLAMA
CONCN
LLAMA
CONCN
LLAMA
MEAN
OF
CONCN
SD
OF
CONCN
#1 #2 #3 #4 #5 #6
0 MIN
5 MIN 56.73 61.22 48.87 46.45 40.47 59.88 52.27 8.28
10 MIN55.95 61.69 44.54 42.07 41.21 60.60 51.01 9.46
15 MIN50.74 58.26 40.21 39.58 38.32 56.31 47.24 8.98
30 MIN48.13 56.23 35.98 35.55 33.95 54.50 44.06 10.13
45 MIN44.18 53.32 37.84 31.28 30.46 49.25 41.05 9.47
1 HR 42.20 50.71 31.29 26.43 26.14 44.67 36.91 10.35
1.5 HR35.91 46.46 28.48 24.36 25.02 41.41 33.61 9.12
2 HR 32.18 41.08 22.20 19.89 20.95 37.23 28.92 9.13
3 HR 27.67 33.94 18.37 15.78 17.78 31.00 24.09 8.28
4 HR 20.94 29.34 14.93 11.23 13.62 25.75 19.30 7.22
6 HR 14.92 23.18 11.05 8.42 9.65 18.73 14.32 5.75
8 HR 7.49 14.01 7.84 6.10 5.50 12.65 8.93 3.53
12 HR 3.11 5.62 3.90 3.26 2.03 6.80 4.12 1.7641
TABLE 10. CLEARANCE IN 1/kg Vs. TIME IN SIX LLAMA'S RECEIVING AN IV DOSE OF 12 mg/kg
AMPICILLIN CALCULATED AFTER THE DISTRIBUTION PHASE HAS ENDED.
TIME CLEARANCE
LLAMA LLAMALLAMA
(lit/hr/kg) MEAN
OF
LLAMA LLAMA LLAMA CLEA-
SD
OF
CLEA-
#3 #1 #2 #4 #5 #6 RANCE RANCE
3 HR0.033 0.019 0.065 0.093 0.046 0.041 0.050 0.026
4 HR0.061 0.015 0.070 0.060 0.075 0.041 0.054 0.021
6 HR0.037 0.012 0.052 0.058 0.048 0.035 0.040 0.016
8 HR0.074 0.025 0.058 0.065 0.078 0.043 0.0570.019
12 HR0.046 0.022 0.058 0.062 0.065 0.034 0.048 0.01742
TABLE 11. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY COMPARTMENTAL MODEL
METHODS FOR AMPICILLIN IN SIX LLAMA'S AFTER IV INJECTION OF 12 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 MeanSD
(3 11-1 0.236 0.261 0.166 0.155 0.261 0.168 0.2080.050
a If' 6.206 0.482 1.024 0.894 0.867 1.250 1.120.58
Al µg /m1 53.31 24.30 29.05 20.84 34.80 50.42 35.4513.58
A2 µg /m1 8.34 15.42 19.13 25.44 10.09 12.30 15.126.35
tir2a h 0.112 1.44 0.676 0.775 0.799 0.555 0.7260.380
tim h 2.94 2.65 4.17 4.48 2.65 4.12 3.500.50
VV 1/kg 0.195 0.302 0.249 0.259 0.273 0.191 0.2450.044
r 0.999 0.999 0.999 0.999 0.999 0.999 0.9990.00043
TABLE 12. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY NON-COMPARTMENTAL
MODEL METHODS FOR AMPICILLIN IN SIX LLAMA'S AFTER IV INJECTION OF 12 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 MeanSD
MRT h 4.21 4.90 5.53 5.53 4.11 5.78 5.01 0.66
CLB 1 /h/kg 0.053 0.038 0.062 0.074 0.078 0.039 0.0570.017
V 1/kg 0.224 0.143 0.373 0.475 0.300 0.230 0.2910.119
AUC0_12pg.h/rri1213.81 295.47 169.71 142.14 145.14 269.72 206.0063.80
AUCB..pg.h/m1227.07 321.71 193.51 163.24 152.89 309.52 228.0072.74
Vd 1/kg 0.222 0.183 0.343 0.407 0.282 0.224 0.2770.08544
FIG 5. MEAN PLASMA CONCENTRATION Vs. TIME PROFILE IN SIX
LLAMA'S GIVEN AN IV DOSE OF 12 mg/kg OF AMPICILLIN INCLUDING
A BEST FIT LINE FIT BY RSTRIP.
0.00 2.00 4.00 6.00 8.00 10.00 12.00
TINE (hr)45
TOBRAMYCIN
Mean plasma concentrations of tobramycin at each sampling time are
shown in table 13. The post-distribution clearance values for tobramycin are
presented in table 14. The clearance values indicate tobramycin follows linear
pharmacokinetics in llama.
Tobramycin plasma concentrations following IV bolus administration
for all six llama's required a two exponential function to characterize the
declining plasma tobramycin concentrations.
The determination of best fit compartmental model and estimates of
the model dependent pharmacokinetic parameters were made as described for
ampicillin. Similarly the non-compartmental model pharmacokinetic parameters
were determined usingstatistical moments theory.Plasma tobramycin
concentrations vs. time curves from all six llama's were analyzed individually.
Meanvaluesforeachpharmacokineticparameterfora
compartmental and a non-compartmental model were computed with their
standard deviation and are shown in tables 15 and 16 respectively. Mean curve
of plasma concentrations after bolus IV administration of the tobramycin is
shown in fig 6.
Pharmacokinetics of tobramycin after IV bolus administration in all
six llama's fitted (correlation coefficient > 0.99) a two compartmental model46
with a = 1.91 ± 0.894 and 13 = 0.162 ± 0.037. The plasma half-life 01120 of
tobramycin was 4.51 ± 1.26 hours. The mean residence time (MRT) of
tobramycin was 5.53 ± 1.79 hours and volume of distribution at steady state
(Vdss) was 0.138 ± 0.049 1/kg.47
TABLE 13. DRUG CONCENTRATION Vs. TIME DATA OF SIX LLAMA'S RECEIVING IV DOSE OF
1 mg/kg OF TOBRAMYCIN.
TIME CONCN
(µg /ml)
Llama
CONCN
Llama
CONCN
Llama
CONCN
Llama
CONCN
LlamaLlama
MEAN
OF
CONCN
SD
OF
CONCN
#1 #2 #3 #4 #5 #6
0 MIN
5 MIN 18.25 19.01 15.5 15.91 13.47 11.17 15.55 2.92
10 MIN18.26 13.31 13.05 13.48 11.48 9.10 13.11 3.01
15 MIN16.12 9.57 11.44 11.71 9.30 8.38 11.09 2.77
30 MIN12.18 7.48 8.86 9.99 7.45 6.44 8.73 2.09
45 MIN11.03 5.64 8.95 9.02 6.61 7.49 8.12 1.92
1 HR 8.34 4.63 7.25 6.79 6.72 4.69 6.40 1.46
1.5 HR 7.82 3.66 6.38 5.61 4.30 4.12 5.31 1.58
2 HR 5.65 4.06 4.74 5.27 3.47 3.23 4.40 0.97
3 HR 4.28 2.9 3.62 4.53 2.69 3.03 3.51 0.66
4 HR 2.63 NA 3.71 3.43 3.07 2.06 3.00 0.58
6 HR 1.93 2.18 2.76 2.39 1.81 1.49 2.09 2.37
8 HR 0.99 1.78 1.24 1.38 1.11 0.93 1.24 0.30
12 HR 0.63 1.40 0.72 0.69 0.79 0.38 0.77 0.3348
TABLE 14. CLEARANCE IN 1/kg Vs. TIME IN SIX LLAMA'S RECEIVING AN IV DOSE OF 1 mg/kg OF
TOBRAMYCIN CALCULATED AFTER THE DISTRIBUTION PHASE HAS ENDED.
TIME CLEARANCE (lit/hr/kg) MEAN SD
OF OF
LlamaLlamaLlamaLlamaLlamaLlamaCLEA- CLEA-
#1 #2 #3 #4 #5 #6 RANCE RANCE
3 HR 0.026 0.0640.016 0.039 0.041 0.009 0.033 0.019
4 HR 0.046NA 0.029 0.015 0.021 0.056 0.033 0.017
6 HR 0.015 0.0300.019 0.052 0.041 0.024 0.029 0.014
8 HR 0.031 0.0190.028 0.025 0.038 0.034 0.031 0.008
12 HR0.011 0.0120.018 0.020 0.014 0.012 0.015 0.00349
TABLE 15. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY COMPARTMENTAL MODEL
METHODS FOR TOBRAMYCIN IN SIX LLAMA'S AFTER IV INJECTION OF 1 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 Mean SD
/3 11-' 0.166 0.101 0.198 0.205 0.152 0.151 0.162 0.037
a 10 0.842 3.302 1.980 2.50 1.60 1.22 1.91 0.894
Al µg /m1 4.31 4.29 7.25 7.81 4.41 3.66 5.29 1.76
A2 µg /m1 14.02 15.96 8.51 9.39 8.91 6.97 10.63 3.52
tinc,
t12/3
h
h
0.823
4.16
0.210
6.86
0.349
3.49
0.280
3.37
0.434
4.56
0.567
4.59
0.443
4.51
0.223
1.26
Vc 1/kg 0.054 0.049 0.060 0.058 0.075 0.094 0.065 0.016
r 0.999 0.998 0.999 0.999 0.997 0.997 0.998 0.00150
TABLE 16. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY NON-COMPARTMENTAL
MODEL METHODS FOR TOBRAMYCIN IN SIX LLAMA'S AFTER IV INJECTION OF 1 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 Mean SD
MRT h 4.12 8.91 4.56 4.47 5.61 5.51 5.53 1.79
CL/3 1 /h/kg 0.024 0.021 0.024 0.024 0.029 0.033 0.026 0.004
Vim 1/kg 0.141 0.210 0.124 0.117 0.190 0.221 0.167 0.045
AUC0.12tig.h/m139.03 34.65 37.40 38.53 29.91 25.98 34.25 5.26
AUC0,o,gg.h/m142.55 47.26 40.76 41.76 34.58 29.93 39.47 6.57
Vdss 1/kg 0.097 0.189 0.112 0.084 0.162 0.184 0.138 0.04951
FIG 6. MEAN PLASMA CONCENTRATION Vs. TIME PROFILE IN SIX
LLAMA'S GIVEN AN IV DOSE OF 1 mg/kg OF TOBRAMYCIN
INCLUDING A BEST FIT LINE FIT BY RSTRIP.
0.00 2.00 4.00 6.00 8.00 10.00 12.00
TINE (hr)52
TRIMETHOPRIM
Mean plasma concentrations of trimethoprim at each sampling time
are shown in table 17. The post distribution clearance values for trimethoprim
are presented in table 18. The clearance values of trimethoprim indicate it
follows linear pharmacokinetics in llama.
TrimethoprimplasmaconcentrationsfollowingIVbolus
administration in all six llama's were best described by a bi-exponential equation.
The determination of best fit compartmental model and estimates of the model
dependent pharmacokinetic parameters were made as described for ampicillin.
Similarly the non-compartmental pharmacokinetic parameters were determined
using statistical moment theory. Plasma trimethoprim concentrations vs. time
curves from all six llama's were analyzed individually.
Mean valuesforeachpharmacokineticparametersfora
compartmental and a non-compartmental model were computed with their
standard deviation and are shown in tables 19 and 20 respectively. Mean
trimethoprim plasma concentrations vs. time after IV bolus administration is
shown in fig 7.
Pharmacokinetics of trimethoprim after bolus IV administration in all
the llama's fitted (correlation coefficient > 0.99) a two compartment model with
a = 2.86 ± 2.27 and (3 = 0.151 ± 0.079.53
The plasma half-life (t1120) of trimethoprim was 4.29 ± 2.52 hours.
The mean residence time (MRT) of trimethoprim was 4.83 ± 1.74 hours and
volume of distribution at steady state (Vdss) was 0.404 ± 0.151 1/kg.54
TABLE 17. DRUG CONCENTRATION Vs. TIME DATA IN SIX LLAMA'S RECEIVING AN IV DOSE OF
3 mg/kg OF TRIMETHOPRIM.
TIME CONCNCONCNCONCNCONCNCONCNCONCNMEANSD
(µg /m1) OF OF
LlamaLlamaLlamaLlamaLlamaLlamaCONCNCONCN
#1 #2 #3 #4 #5 #6
0 MIN
5 MIN 15.99 14.29 14.95 15.35 16.41 8.98 14.33 2.71
10 MIN14.86 9.21 14.34 9.79 14.17 7.11 11.58 3.27
15 MIN11.58 10.45 12.39 10.83 12.1 6.37 10.62 2.20
30 MIN10.42 8.6 10.2 9.61 9.75 5.28 8.98 1.91
45 MIN10.46 7.78 9.49 8.00 9.28 4.78 8.3 1.98
1 HR 9.1 6.29 9.32 3.38 8.22 3.62 6.65 2.66
1.5 HR 7.91 5.85 6.86 5.46 7.17 3.29 6.09 1.63
2 HR 7.73 5.08 6.16 4.24 6.2 2.31 5.28 1.87
3 HR 6.05 4.05 6.10 3.16 5.05 1.98 4.4 1.64
4 HR 4.57 2.8 4.73 2.36 4.51 1.21 3.36 1.44
6 HR 2.91 1.46 2.88 1.31 2.65 0.68 1.98 0.97
8 HR 1.81 1.09 1.99 0.61 1.98 0.75 1.37 0.59
12 HR 0.97 0.65 1.05 0.34 1.17 0.26 0.74 0.3955
TABLE 18. CLEARANCE IN 1/kg Vs. TIME IN SIX LLAMA'S RECEIVING AN IV DOSE OF 3 mg/kg OF
TRIMETHOPRIM CALCULATED AFTER THE DISTRIBUTION PHASE HAS ENDED.
TIME
LlamaLlama
CLEARANCE (lit/hr/kg)
LlamaLlamaLlama Llama
MEAN
OF
CLEA-
SD
OF
CLEA-
#1 #2 #3 #4 #5 #6 RANCERANCE
3 HR 0.062 0.129 0.116 0.003 0.062 0.291 0.111 0.098
4 HR 0.071 0.210 0.115 0.072 0.035 0.338 0.140 0.113
6 HR 0.053 0.181 0.114 0.069 0.079 0.030 0.088 0.053
8 HR 0.059 0.084 0.145 0.052 0.044 0.293 0.113 0.095
12 HR 0.039 0.072 0.057 0.044 0.040 NA(*) 0.050 0.01256
TABLE 19. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY COMPARTMENTAL MODEL
METHODS FOR TRIMETHOPRIM IN SIX LLAMA'S AF1ER IV INJECTION OF 3 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 MeanSD
0 11-' 0.216 0.074 0.256 0.187 0.176 0.246 0.1510.079
a 11-' 6.97 0.45 3.53 2.46 2.55 1.22 2.862.27
Al µg /m1 11.25 1.48 5.96 9.44 8.60 2.02 6.464.03
A2 µg /m1 9.36 9.27 10.77 6.97 8.71 6.72 8.63 1.54
tin°,
t1,20
h
h
0.099
3.21
1.53
9.35
0.196
2.71
0.281
3.69
0.271
3.95
0.568
2.82
0.49
4.29
0.532
2.52
V,
r
1/kg 0.146
0.999
0.279
0.998
0.179
0.998
0.183
0.999
0.173
0.999
0.343
0.998
0.217
0.998
0.075
0.00157
TABLE 20. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY NON-COMPARTMENTAL
MODEL METHODS FOR TRIMETHOPRIM AFTER IV INJECTION OF 3 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 Mean SD
MRT h 4.51 7.79 3.49 5.07 5.35 2.76 4.83 1.74
CLB 1 /h/kg 0.056 0.074 0.114 0.056 0.057 0.218 0.096 0.063
Vdarea 1/kg 0.260 0.980 0.445 0.301 0.326 0.880 0.532 0.315
AUC0_12tig.h/m149.51 32.22 25.27 47.91 46.45 12.57 35.66 14.89
AUC0_,,,p.g.h/m153.41 40.55 26.35 53.23 52.40 13.72 39.94 16.63
Vd 1/kg 0.254 0.576 0.398 0.286 0.306 0.604 0.404 0.15158
FIG 7. MEAN PLASMA CONCENTRATION Vs. TIME PROFILE IN SIX
LLAMA'S GIVEN AN IV DOSE 3 mg/kg OF TRIMETHOPRIM INCLUDING
A BEST FIT LINE FIT BY RSTRIP.
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ENROFLOXACIN
Mean plasma concentration of enrofloxacin at each sampling time are
shown in table 21. The post distribution clearance values for enrofloxacin are
presented in table 22. The clearance values of enrofloxacin indicate it follows
linear pharmacokinetics in llama.
Enrofloxacin plasma concentrations following bolus IV administration
for all six llama's required a two exponential function to characterize the
declining enrofloxacin plasma concentrations.
The determination of best fit compartmental model and estimation
of the model dependent pharmacokinetic parameters were made as described for
ampicillin. Similarly the non-compartmental model pharmacokinetic parameters
were determined usingstatistical moment theory.Plasma enrofloxacin
concentrations vs. time curves from all six llama's were analyzed individually.
Mean valuesforeachpharmacokineticparametersfora
compartmental and a non-compartmental model were computed with their
standard deviation and are shown in tables 23 and 24 respectively. Mean
enrofloxacin plasma concentrations vs. time curve after IV bolus administration
is shown in fig 8.
Pharmacokinetics of enrofloxacin after bolus IV administration fitted
correctly in all llama's (correlation coefficient > 0.99) to a two compartment60
model with a = 2.48 ± 1.21 and (3 = 0.205 ± 0.069. The plasma half-life 01,20
enrofloxacin was 3.94 ± 2.13 hours. The mean residence time (MRT) of
enrofloxacin was 4.95 ± 2.87 hours and volume of distribution at steady state
was 0.346 ± 0.098 1/kg.61
TABLE 21. DRUG CONCENTRATION Vs. TIME DATA OF SIX LLAMA'S RECEIVING AN IV DOSE OF
5 mg/kg OF ENROFLOXACIN.
TIME CONCN
(µg /ml)
Llama
CONCN
Llama
CONCN
Llama
CONCN
Llama
CONCN
Llama
CONCN
Llama
MEAN
OF
CONCN
SD
OF
CONCN
#1 #2 #3 #4 #5 #6
0 MIN
5 MIN 25.00 30.5 35.1 25.35 34.67 24.95 29.26 4.43
10 MIN22.39 17.86 29.46 24.96 27.89 22.17 24.12 4.22
15 MIN17.6 15.6 24.87 22.55 27.53 18.36 21.08 3.63
30 MIN15.18 11.72 20.59 18.59 18.25 14.86 16.53 3.28
45 MIN12.26 10.69 17.43 15.91 15.78 12.26 14.05 2.66
1 HR 9.16 8.62 13.02 12.46 15.55 11.82 11.77 2.56
1.5 HR 9.11 8.02 11.33 9.14 12.91 8.08 9.76 1.97
2 HR 8.63 7.42 8.8 7.85 10.07 7.06 8.30 1.09
3 HR 4.46 6.47 7.00 4.37 8.7 3.95 5.82 1.87
4 HR 3.65 6.09 5.86 4.06 7.15 3.61 5.07 1.48
6 HR 3.05 4.79 3.89 3.2 5.8 2.68 3.90 1.18
8 HR 1.23 NA 1.05 1.3 3.48 1.31 1.67 1.34
12 HR 0.56 3.27 0.65 0.59 1.55 0.94 1.26 1.0562
TABLE 22. CLEARANCE IN 1/kg Vs. TIME IN SIX LLAMA'S RECEIVING AN IV DOSE OF 5 mg/kg OF
ENROFLOXACIN CALCULATED AFTER THE DISTRIBUTION PHASE HAS ENDED.
TIME
LlamaLlama
CLEARANCE (lit/hr/kg)
LlamaLlamaLlamaLlama
MEAN
OF
CLEA-
SD
OF
CLEA-
#1 #2 #3 #4 #5 #6 RANCERANCE
3 HR 0.219 0.069 0.173 0.053 0.039 0.241 0.132 0.098
4 HR 0.069 0.031 0.023 0.041 0.052 0.038 0.042 0.016
6 HR 0.031 0.061 0.036 0.047 0.028 0.063 0.044 0.015
8 HR 0.146 NA 0.128 0.132 0.066 0.146 0.124 0.029
12 HR 0.054 0.044 0.057 0.027 0.051 0.035 0.045 0.01263
TABLE 23. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY COMPARTMENTAL MODEL
METHODS FOR ENROFLOXACIN IN SIX LLAMA'S AFTER IV INJECTION OF 5 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 MeanSD
0 11-' 0.254 0.089 0.232 0.305 0.192 0.161 0.2050.069
a 11-' 2.23 4.31 1.32 2.74 3.22 1.07 2.48 1.21
Al gg/in1 10.86 8.92 9.45 16.86 16.02 5.76 11.314.31
A2 µg /ml 16.02 23.28 19.17 21.62 23.60 18.24 20.323.01
ti/2a h 0.310 0.161 0.525 0.253 0.215 0.647 0.3520.191
t1/2# h 2.73 7.76 2.98 2.27 3.61 4.32 3.94 2.13
Vc 1/kg 0.186 0.155 0.175 0.130 0.126 0.208 0.1630.032
r 0.999 0.995 0.999 0.999 0.999 0.999 0.9980.00164
TABLE 24. PHARMACOKINETIC PARAMETER VALUES OBTAINED BY NON-COMPARTMENTAL
MODEL METHODS FOR ENROFLOXACIN AFTER IV INJECTION OF 5 mg/kg.
Para- Units Llama No.
meter 1 2 3 4 5 6 Mean SD
MRT h 3.44 10.63 3.37 2.91 4.81 4.52 4.95 2.87
CLB 1 /h/kg 0.100 0.048 0.091 0.079 0.055 0.094 0.078 0.021
V 1/kg 0.394 0.534 0.389 0.259 0.287 0.588 0.408 0.130
AUC0_12gg.h/m147.92 71.06 52.65 61.73 82.45 47.69 60.58 13.98
AUC0_,,1.4g.h/m149.96 105.24 55.14 63.16 90.78 52.91 69.53 22.95
Vd 1/kg 0.344 0.505 0.305 0.231 0.265 0.427 0.346 0.09865
FIG 8. MEAN PLASMA CONCENTRATION Vs. TIME PROFILE IN SIX
LLAMA'S GIVEN AN IV DOSE OF 5 mg/kg OF ENROFLOXACIN
INCLUDING A BEST FIT LINE BY RSTRIP.
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AMPICILLIN
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The elimination half-life (t120) of ampicillin in llamas was 3.50 ± 0.50
hours, where as half-lives of 1.09, 0.79, 0.96 and 1.6 hours have been reported for
human, sheep, mice and horses respectively (11-14). The mean residence time
(MRT) in llamas was 5.01 ± 0.66 hours, where as mean residence times of 0.40
and 0.36 hours have been reported for human and sheep respectively (11,14).
The volume of distribution at steady state (VAS) in llamas was 0.277 ± 0.085
1/kg, where as 0.269, 0.156, 0.377 and 2.5 1/kg has been reported for human,
sheep, mice and horses respectively (11-14). Ampicillin is eliminated more slowly
from llamas than other ruminants.
The dose and dosing interval of ampicillin in sheep is 10 mg/kg/day
and 40 mg/kg/day in horses (11,12). In humans ampicillin dosing regime is 250
mg every 6 hours orally for a 70 kg person. Ampicillin given 12 mg/kg of body
weight every 12 hours administered parenterally to llamas provides ampicillin
concentrations effective against ampicillin sensitive bacteria. From this dosing
regime a C. (peak) and Cink, (trough) plasma concentrations of 47 ± 15 µg /ml
and 3.9 ± 1.3 µg /m1 would be obtained at steady state.67
A reduction in ampicillin dosing to 12 mg/kg/day or 6 mg/kg every
12 hours appears to be appropriate for most microbial infections in llamas.
TOBRAMYCIN
The elimination half-life (tm) tobramycin in llamas was 4.51 ± 1.26
hours, where as half-lives of 1.84 and 1.59 hours have been reported for cats and
humans respectively (15,16). The mean residence time (MRT) in llamas was 5.53
± 1.79 hours, where as mean residence time of 1.75 hours has been reported in
cats (15). The volume of distribution at steady state (Vass) in llamas was 0.138 ±
0.049 1/kg, compared to the volume of distribution at steady state of 0.10 and
0.241 1/kg has been reported for cats and humans respectively (15,16).
When determining tobramycin dosage regimen, the frequency of
administration of tobramycin depends on the effective blood concentration
desired. Minimal toxic concentrations of tobramycin have not been determined
in the llama. In people, it is recommended that peak plasma concentration be
< 12 µg /m1 (46). Dosage recommendations calculated to induce an average
steady-state plasma concentration (C" ave) that is within the therapeutic range
(4 to 8 tig/rn1), for many severe infections (46). Pharmacokinetic values
determined after IV administration of tobramycin in llamas were used for this
calculation.68
The dose and dosing interval of tobramycin in cats is 2 mg/kg every
8 hours (15). The human dose and dosing interval of 1 mg of tobramycin/kg of
body weight given IV, every 8 hour, will yield a C" ave of approximately 5.0
µg /ml which is within the therapeutic range. The peak (C.) plasma tobramycin
concentration in llama will be approximately 10.0 ± 4.0 µg /ml and the trough
(Cm;) plasma concentration will be 2.7 ± 1.1 µg /ml following a dosing regimen
of 1 mg/kg of body weight every 8 hours administered parenterally. This trough
level in humans may cause nephrotoxicity and would need to be reduced to half
this value by reducing the dose in half. Adequate therapy could still be obtained
for most bacteria with peak level of 5 ktg/m1 and a trough of about 2 µg /ml.
Nephrotoxicity in llamas has not been reported as yet to be a concern after
aminoglycoside administration and may not occur.
TRIMETHOPRIM
The elimination half-life (t112) of trimethoprim in llamas was 4.29 ±
2.52 hours, where as half-lives of 1.65 and 3.92 and 14.6 hours have been
reported for rat, horse and man respectively (17,18,49). The mean residence time
(MRT) in llamas was 4.83 ± 1.74 hours, compared to the mean residence time
of 0.86 hours has been reported in rat (17). The volume of distribution at steady69
state (V68) in llamas was 0.404 ± 0.151 1/kg, where as volume of distribution at
steady state of 2.03 1/kg and 1.78 1/kg has been reported in rat and man (17,49).
On the basis of pharmacokinetic profile observed, trimethoprim
3 mg/kg of body weight every 12 hours administered parenterally should provide
trimethoprim concentrations effective against trimethoprim sensitive bacteria.
From this dosing regimen a Cm. (peak) and Qi. (trough) plasma concentrations
of 8.8 ± 3.8 µg /m1 and 1.5 ± 0.6 µg /m1 respectively would be obtained at steady
state. This dosing schedule is efficacious in attaining therapeutic levels against
the most common pathogens reported earlier (47). The minimum inhibitory
concentrations for trimethoprim against E. coli, Klebriella, Enterobacter and
Proteus range from 1.0 µg /ml to 4.0 µg /m1 (50).
The dose and dosing interval of trimethoprim in horse is 4 mg/kg
every day in horses (18). In man, trimethoprim dose and dosing interval is
3 mg/kg every 6 hours (49).
ENROFLOXACIN
The elimination half-life (two) of enrofloxacin in llamas was 3.94 ±
2.13 hours, where as half-lives of 4.1, 18.7, 2.7, 2.5 and 24.4 hours have been
reported for turkey, chicken, calf, rabbit and fish respectively (7-10). The mean
residence time (MRT) in llamas was 4.95 ± 2.87 hours, where as mean residence70
time of 30.2 hours has been reported in fish (10). The volume of distribution at
steady state (Vdsg) in llamas was 0.346 ± 0.098 1/kg, where as volume of
distribution at steady state of 0.63, 0.93 and 2.77 1/kg has been reported for calf,
rabbit and fish respectively (8-10).
Enrofloxacin has a broad spectrum of antimicrobial activity, with
minimal inhibitory concentration (MIC) values ranging from 0.008 to 0.75 µg /m1
for > 100 various bacterial pathogens and enrofloxacin achieved concentrations
higher than the MIC in several tissues (48). Llamas which are a species that
frequently have infections caused by organisms susceptible to enrofloxacin, the
plasma concentrations of enrofloxacin after IV bolus administration were higher
than the mean MIC values needed for many organisms. Moreover maximal
plasma concentrations remained high over several hours.
Enrofloxacin administered parenterally at 5 mg/kg of body weight
every 12 hours should provide enrofloxacin concentrations effective against most
bacterial pathogens. From this dosing regimen a C. (peak) and Qi. (trough)
plasma concentrations of 15 ± 4.8 Ag/m1 and 1.4 ± 0.4 µg /m1 can be obtained
at steady state.
The dose and dosing interval of enrofloxacin in calf and rabbits is
5 mg/kg every 12 hours (8,9), compared to fish it is 5 mg/kg/day (10). In dogs
enrofloxacin dosing regimen of 2.5 mg/kg every 12 hours or 5 mg/kg/day orally
has been reported (48).71
CONCLUSION
Doses given in this study provided adequate anti-microbial drug
concentrations in llamas. Dose and dosing regimens outlined are adequate but
not always extrapolated directly from other ruminant animals. In some instances
the dose and dosing interval matched human dosing more closely than ruminant
animals but in other instances this was not the case. Anti-microbial dosing in
llamas still needs further study to elucidate better therapeutic regimens.72
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